Oncolytic virus company Binhui Bio completed nearly 300 million yuan in B+ round of financing

It was reported on April 19 that Wuhan Binhui Biotechnology Co., Ltd. recently completed the B+ round of financing. Following the completion of the B round of financing of 600 million yuan in early 2021, it was led by Yangzijiang Pharmaceutical Group, and invested by Denuo Capital and Xiaoming. Nearly 300 million yuan of financing jointly invested by , Jointown Group and Hubei High Investment.

According to public information, Binhui Bio is an enterprise in the field of tumor immunotherapy oncolytic virus subdivision. The first candidate drug BS001 (OH2) injection developed by it has been approved by China’s NMPA and the US FDA successively. Clinical Trials. OH2 injection is an oncolytic virus candidate drug selected for herpes simplex virus type II (HSV2) as a carrier and entered into clinical trials. Novel oncolytic virus drug candidates.

In 2021, Binhui Bio will build a new nucleic acid drug and protein drug platform based on the oncolytic virus immunotherapy platform. The two newly established R&D platforms are based on innovative technologies such as LNP delivery system with independent intellectual property rights, various RNA structures, trimeric protein structures, and protein purification systems for molecular clip antibody preparation. It has the advantages of strong specificity, rich targets, long-lasting efficacy, and high success rate of clinical development.